Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that when ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck's stock trades at a low valuation as investors ... The big question is, even if successful, whether many patients will opt for the new form of treatment, which may be more convenient ...

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment DURHAM, N.C., March 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States ...

March 11 (Reuters) - A federal judge ruled in favor of Merck (MRK.N), opens new tab in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug giant announced Tuesday. Merck has opened a $1 billion, 225,000-square ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options ...

Hengrui Pharma signed the agreement with Merck (NYSE: MRK) — known as MSD outside of the United States and Canada — for HRS-5346, its investigational oral small molecule Lipoprotein(a), or Lp ...

Merck added that its drugs Janumet and Janumet XR were selected for the second round of negotiations, with those prices slated to take effect in January 2027. "The company expects that in 2026 ...